Cargando…

P546: MACHINE LEARNING AND RESPONSE TO INDUCTION CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

Detalles Bibliográficos
Autores principales:	Elhaddad, Heba, Chiriches, Claudia, Watts, Katie, Giles, Peter, Gilkes, Amanda, Ruthardt, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429773/ http://dx.doi.org/10.1097/01.HS9.0000969092.93079.e9

Ejemplares similares

Understanding a high-risk acute myeloid leukemia by analyzing the interactome of its major driver mutation
por: Chiriches, Claudia, et al.
Publicado: (2022)

Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia
por: Chiriches, Claudia, et al.
Publicado: (2022)

P456: LEUKEMOGENESIS BY AML-SPECIFIC DRIVER MUTATIONS WITHIN DNMT3A, IDH2 AND NPM1
por: Mehmetbeyoglu, Ecmel, et al.
Publicado: (2023)

594. Micafungin Prophylaxis in Acute Myeloid Leukemia Adult Patients Undergoing Induction Chemotherapy
por: Ross, Justine Abella, et al.
Publicado: (2021)

P552: MEASURABLE RESIDUAL DISEASE DETECTED BY WT1 IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN CHILDREN WITH ACUTE MYELOID LEUKEMIA
por: Elsherif, Mariam, et al.
Publicado: (2023)

P581: A MARKOV DECISION ANALYSIS OF AZACITIDINE AND VENETOCLAX VERSUS INDUCTION CHEMOTHERAPY FOR THE TREATMENT OF MEDICALLY-FIT PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Ravindran, Mithunan, et al.
Publicado: (2023)

546. Capturing Clinician’s Experiences Repurposing Drugs to Inform Future Studies During COVID-19
por: Duggal, Mili, et al.
Publicado: (2020)

Papular eruption after induction chemotherapy for acute myeloid leukemia
por: Novice, Taylor, et al.
Publicado: (2020)

P417: GENOMIC LANDSCAPE AND PROGNOSIS IN OLDER ACUTE MYELOID LEUKEMIA PATIENTS NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY
por: Jahn, Ekaterina, et al.
Publicado: (2023)

P534: FIRST-IN-HUMAN TRIAL OF TOCILIZUMAB IN COMBINATION WITH A STANDARD INDUCTION CHEMOTHERAPY IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS: THE PHASE 1 TOCILAM STUDY.
por: Peterlin, Pierre, et al.
Publicado: (2023)

P475: EMERGING LEUKEMIA ASSOCIATED IMMUNOPHENOTYPES (LAIPS) IN BONE MARROW OF ACUTE MYELOID LEUKEMIA PATIENTS AFTER INTENSIVE CHEMOTHERAPY.
por: Lam Ngai, Lok, et al.
Publicado: (2023)

Fatal Idiopathic Hyperammonemia after Induction Chemotherapy for Acute Myeloid Leukemia
por: Angelo, Christophe, et al.
Publicado: (2020)

Neutropenic Enterocolitis Complicating Induction Chemotherapy in an Acute Myeloid Leukemia Patient
por: Groudan, Kevin, et al.
Publicado: (2021)

Applications of Machine Learning in Chronic Myeloid Leukemia
por: Elhadary, Mohamed, et al.
Publicado: (2023)

Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
por: Cherry, Evan M., et al.
Publicado: (2021)

P501: ISATUXIMAB PLUS CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA OR ACUTE MYELOID LEUKEMIA (ISAKIDS): INTERIM EFFICACY ANALYSIS
por: Baruchel, André, et al.
Publicado: (2023)

742. Breakthrough Invasive Fungal Infections with Isavuconazonium Sulfate versus Voriconazole as Primary Antifungal Prophylaxis in Patients with Acute Myeloid Leukemia (AML) who Received Induction Chemotherapy
por: Singam, Hareesh v, et al.
Publicado: (2020)

P515: A REAL-WORLD EVALUATION OF TREATMENT PATTERNS AND OUTCOMES OF ACUTE MYELOID LEUKEMIA INDUCTION THERAPIES IN THE COMMUNITY SETTING
por: Maher, Keri, et al.
Publicado: (2023)

Novel Translocation in Acute Myeloid Leukemia: Case Report and Review of Risk-Stratification and Induction Chemotherapy in Patients With Acute Myeloid Leukemia
por: Jeha, George M., et al.
Publicado: (2020)

P1530: CORTICOSTEROIDS FOR INFLAMMATORY RESPONSES DURING INDUCTION CHEMOTHERAPY IN MYELOID MALIGNANCIES ARE NOT ASSOCIATED WITH INCREASED INCIDENCE OF INVASIVE FUNGAL INFECTIONS
por: Migchelbrink, Jorne, et al.
Publicado: (2023)

P484: GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. UPDATED TOXICITY AND INTERIM SURVIVAL ANALYSIS FROM THE NCRI AML19V2 “MIDOTARG” PILOT TRIAL
por: Russell, Nigel, et al.
Publicado: (2023)

Inclusive jet production at $\sqrt{s} = 546 GeV$
por: Arnison, Geoffrey T J, et al.
Publicado: (1985)

P510: PREDICTORS OF RESPONSE AND OUTCOME IN PATIENTS WITH REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA RECEIVING VENETOCLAX WITH NON-INTENSIVE CHEMOTHERAPY
por: Krüger, Katja, et al.
Publicado: (2023)

Hepatic copper concentrations in 546 dogs (1982–2015)
por: Strickland, Jaimie M., et al.
Publicado: (2018)

546 Health Disparities Among Rural Burn Patients
por: Duggan, Robert P, et al.
Publicado: (2022)

546. Therapeutic Effect of Regdanvimab in Patients with Mild to Moderate COVID-19: Day 28 Results from a Multicentre, Randomised, Controlled Pivotal Trial
por: Ison, Michael G, et al.
Publicado: (2021)

1301. Breakthrough Invasive Fungal Infections based on CYP2C19 Levels in Patients Who were on Voriconazole as Primary Antifungal Prophylaxis in Acute Myeloid Leukemia (AML) undergoing Induction Chemotherapy
por: Singam, Hareesh v, et al.
Publicado: (2020)

Outcomes of 1st Remission Induction Chemotherapy in Acute Myeloid Leukemia Cytogenetic Risk Groups
por: Zehra, Samreen, et al.
Publicado: (2016)

Screening for an underlying myeloproliferative neoplasm in patients with thrombocytosis post-induction chemotherapy for acute myeloid leukemia
por: Langabeer, Stephen E.
Publicado: (2020)

Sweet's syndrome during induction chemotherapy for acute myeloid leukemia – case report and mini review
por: Fonseca, Gabriela Spacek da, et al.
Publicado: (2021)

Redefining Remission Induction Chemotherapy Ineligibility by Early Mortality in De Novo Acute Myeloid Leukemia
por: Li, You-Cheng, et al.
Publicado: (2021)

Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy
por: Rodríguez-Macías, Gabriela, et al.
Publicado: (2023)

Preludes and fugues BWV 544, 541, 546, 542 and 536
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1992)

Comparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia
por: Yoon, Jae-Ho, et al.
Publicado: (2017)

P558: ABSOLUTE LYMPHOCYTE COUNT IS AN INDEPENDENT SURVIVAL PREDICTOR COMPARED TO MINIMAL RESIDUAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY
por: Cristiano, Gianluca, et al.
Publicado: (2023)

P424: LANDSCAPE OF CHROMATIN ACCESSIBILITY IN ACUTE MYELOID LEUKEMIA
por: Ochi, Yotaro, et al.
Publicado: (2023)

Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia
por: Tiong, Ing S., et al.
Publicado: (2021)

546. COVID-19 Monoclonal Antibody Use at a Stand Alone Children’s Hospital
por: Stimes, Grant T, et al.
Publicado: (2023)

Colonization with multidrug resistant organisms determines the clinical course of patients with acute myeloid leukemia undergoing intensive induction chemotherapy
por: Ballo, Olivier, et al.
Publicado: (2019)

Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re‐induction chemotherapy
por: Ruan, Min, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5hga38lcn47joeqd33d48pdcor